Patents Represented by Attorney, Agent or Law Firm Kenneth Barovsky
  • Patent number: 6831156
    Abstract: The present invention relates to a molecular motor actin binding protein, in particular, to Nuclear Myosin I&bgr; (NMI&bgr;) containing a 16 amino acid N-terminal extension involved in transcription. More particularly, this invention is directed to a molecule with oligonucleotide sequence coding for a protein nuclear Myosin I&bgr; (NMI&bgr;) containing a 16 amino acid N-terminal extension that co-localizes with, and forms functional complexes with, RNA polymerase II. This invention is also directed to polyclonal and monoclonal antibodies to the 16 amino acid N-terminal extension that block in vitro RNA synthesis. This invention is also directed to administration to a cell of polyclonal or monoclonal antibodies to the NMI&bgr; 16 amino acid N-terminal extension sequence or to an epitope within that sequence to inhibit transcription. Other inhibitors are also suitable. This invention may be used to treat illness through targeted inhibition of cell proliferation.
    Type: Grant
    Filed: June 27, 2001
    Date of Patent: December 14, 2004
    Inventors: Primal de Lanerolle, Grzegorz Nowak, Lidija Pestic-Dragovich, Ljuba Stojilkovic, Pavel Hozak
  • Patent number: 5866362
    Abstract: Protein aggregates obtained by a process comprising culturing a host cell that expresses a desired protein in a medium comprising an effective amount of Cu.sup.++ and wherein the desired protein forms inclusion bodies in the host cell.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: February 2, 1999
    Assignee: Chiron Corporation
    Inventors: Lawrence S. Cousens, Patricia Tekamp-Olson
  • Patent number: 5853974
    Abstract: Methods and compositions for enhancing the chemiluminescence from a stable 1,2-dioxetane triggered to produce a chemiluminescence are disclosed. Indirect, competitive nucleic acid hybridization assay formats are also described that employ these methods and compositions.
    Type: Grant
    Filed: March 5, 1996
    Date of Patent: December 29, 1998
    Assignee: Chiron Corporation
    Inventor: Patrick J. Sheridan
  • Patent number: 5843472
    Abstract: Drug delivery systems for the transdermal administration of tamsulosin are described. The systems are in the form of laminated patches having one or more reservoirs comprised of a polymeric adhesive material containing a tamsulosin formulation. The invention also relates to a method for treating benign prostatic hypertrophy (BPH) and related conditions and diseases, by administering tamsulosin transdermally, to tamsulosin-containing pharmaceutical compositions for transdermal administration of the drug and to a low-temperature method for manufacturing a tamsulosin-containing transdermal delivery system.
    Type: Grant
    Filed: February 28, 1997
    Date of Patent: December 1, 1998
    Assignee: Cygnus, Inc.
    Inventors: Xinghang Ma, Jay Audett, Pravin L. Soni, Noel Singh, Susan E. Bailey
  • Patent number: 5843718
    Abstract: Novel polyketides and novel methods of efficiently producing both new and known polyketides, using recombinant technology, are disclosed. In particular, a novel host-vector system is described which is used to produce polyketide synthases which in turn catalyze the production of a variety of polyketides.
    Type: Grant
    Filed: March 31, 1997
    Date of Patent: December 1, 1998
    Assignees: The Leland Stanford Junior University, The John Innes Institute
    Inventors: Chaitan Khosla, David A. Hopwood, Susanne Ebert-Khosla, Robert McDaniel, Hong Fu
  • Patent number: 5789203
    Abstract: Recombinant protein complexes having human Factor VIII:C activity are expressed in a eukaryotic host cell by transforming the host cell with first and second expression cassettes encoding a first polypeptide substantially homologous to human Factor VIII:C A domain and a second polypeptide substantially homologous to human Factor VIII:C C domain, respectively. In the present invention, the first polypeptide may be extended having at its C-terminal a human Factor VIII:C B domain N-terminal peptide, a polypeptide spacer of 3-40 amino acids, and a human Factor VIII:C B domain C-terminal peptide. Expression of the second polypeptide is improved by employing an .alpha..sub.1 -antitrypsin signal sequence.
    Type: Grant
    Filed: June 27, 1994
    Date of Patent: August 4, 1998
    Assignees: Chiron Corporation, Novo Nordisk A/S
    Inventors: Barbara Chapman, Rae Lyn Burke, Mirella Ezban Rasmussen, Jan Moller Mikkelson
  • Patent number: 5780227
    Abstract: A method of preparing a homogeneous alkaline phosphatase-oligonucleotide probe conjugate having high specific enzyme activity for use in nucleic acid hybridization assays is disclosed. Indirect, competitive nucleic acid hybridization assay formats are also described.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: July 14, 1998
    Inventors: Patrick J. Sheridan, Julio C. Gagne, Mary L. Anderson
  • Patent number: 5780610
    Abstract: Methods are provided for substantially reducing background signals encountered in nucleic acid hybridization assays. The method is premised on the elimination or significant reduction of the phenomenon of nonspecific hybridization, so as to provide a detectable signal which is produced only in the presence the target polynucleotide of interest. In addition, a novel method for the chemical synthesis of isoguanosine or 2'-deoxy-isoguanosine is provided. The invention also has applications in antisense and aptamer therapeutics and drug discovery.
    Type: Grant
    Filed: February 3, 1997
    Date of Patent: July 14, 1998
    Inventors: Mark L. Collins, Thomas Horn, Patrick J. Sheridan, Brian D. Warner, Michael S. Urdea
  • Patent number: 5629203
    Abstract: Efficient integration of heterologous DNA into yeast genomic DNA is accomplished at high copy number by targeting integration vectors to dispersed repetitive elements such as DELTA sequences, Ty elements, or tRNA DNA sequences present in the host cell genome.
    Type: Grant
    Filed: November 30, 1994
    Date of Patent: May 13, 1997
    Assignee: Chiron Corporation
    Inventor: Jeffrey R. Shuster
  • Patent number: 5545730
    Abstract: Novel reagents useful in a variety of biochemical and chemical contexts, including nucleic hybridization assays and chemical phosphorylation of hydroxyl-containing compounds. The reagents are particularly useful for introducing cleavable sites and/or abasic sites into oligonucleotide or polynucleotide chains.
    Type: Grant
    Filed: May 8, 1995
    Date of Patent: August 13, 1996
    Assignee: Chiron Corporation
    Inventors: Michael S. Urdea, Thomas Horn
  • Patent number: 5491065
    Abstract: Monoclonal antibodies that bind to an apparent conformational epitope associated with recombinant or native dimeric M-CSF with concomitant neutralization of biological activity, which monoclonal antibodies are substantially unreactive with biologically inactive forms of M-CSF including monomeric and chemically derivatized dimeric M-CSF, are described. Methods of using the antibodies in assays for detection of dimeric M-CSF are also described.
    Type: Grant
    Filed: November 19, 1993
    Date of Patent: February 13, 1996
    Assignee: Cetus Oncology Corporation
    Inventors: Robert F. Halenbeck, Kirston E. Koths, Joseph W. Wrin